133 related articles for article (PubMed ID: 38448766)
1. Dosing lutetium Lu 177-dotatate for a hemodialysis patient.
Taylor L; Meades R; Quigley AM; Toumpanakis C; Goodlad C; Davenport A
Hemodial Int; 2024 Apr; 28(2):247-252. PubMed ID: 38448766
[TBL] [Abstract][Full Text] [Related]
2. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
3. Imaging Advancements in Nuclear Medicine: Pancreatic Neuroendocrine Tumor Localization and Treatment.
Stephens CP; Beam AS; Gray Z; Mansfield J; Reves L; Gray J; Stamey A; Collum M; Vijayakumar V
Radiol Technol; 2022; 93(5):431-436. PubMed ID: 35508408
[TBL] [Abstract][Full Text] [Related]
4. An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (
Kovan B; Özkan ZG; Demir B; Tunçman D; Işik EG; Şimşek DH; Büyükkaya F; Türkmen C; Şanli Y
Cancer Biother Radiopharm; 2022 Feb; 37(1):17-22. PubMed ID: 34134512
[No Abstract] [Full Text] [Related]
5. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
[TBL] [Abstract][Full Text] [Related]
6. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
Clin Nucl Med; 2022 Jun; 47(6):503-511. PubMed ID: 35507433
[TBL] [Abstract][Full Text] [Related]
7. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
Am J Clin Oncol; 2022 Jun; 45(6):233-242. PubMed ID: 35507413
[TBL] [Abstract][Full Text] [Related]
8. Patient Release and Instructions for Lutetium Dotatate Radiopharmaceutical Therapy.
Underwood J; Sturchio G; Arnold S
Health Phys; 2021 Aug; 121(2):160-165. PubMed ID: 33899756
[TBL] [Abstract][Full Text] [Related]
9. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
[TBL] [Abstract][Full Text] [Related]
10. Combined use of
Fu J; Qiu F; Stolniceanu CR; Yu F; Zang S; Xiang Y; Huang Y; Matovic M; Stefanescu C; Tang Q; Wang F
J Neuroendocrinol; 2022 Apr; 34(4):e13109. PubMed ID: 35304807
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Two Types of Amino Acid Solutions on
Lambert M; Dierickx L; Brillouet S; Courbon F; Chatelut E
Curr Radiopharm; 2022; 15(2):164-172. PubMed ID: 35105299
[TBL] [Abstract][Full Text] [Related]
12. Lutetium-177 Radiopharmeceutical Therapy Extravasation Lessons Learned.
Berry K; Kendrick J
Health Phys; 2022 Aug; 123(2):160-164. PubMed ID: 35318982
[TBL] [Abstract][Full Text] [Related]
13. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Kulkarni HR; Schuchardt C; Baum RP
Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
[TBL] [Abstract][Full Text] [Related]
14.
Hervás I; Bello P; Falgas M; Del Olmo MI; Torres I; Olivas C; Vera V; Oliván P; Yepes AM
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):91-98. PubMed ID: 27889527
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.
Boucher JE; Sommers R
Clin J Oncol Nurs; 2018 Oct; 22(5):565-568. PubMed ID: 30239510
[TBL] [Abstract][Full Text] [Related]
16. Repurposed Effect of
Elajami MK; Burton LP; Bahmad HF; Chaaya G; Schwartz M
Curr Oncol; 2022 Oct; 29(10):7552-7557. PubMed ID: 36290871
[TBL] [Abstract][Full Text] [Related]
17. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
[TBL] [Abstract][Full Text] [Related]
18. Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy.
de Vries-Huizing DMV; Cheung ZJ; Hendrikx JJMA; Donswijk ML; Versleijen MWJ
Clin Nucl Med; 2024 May; 49(5):454-456. PubMed ID: 38465961
[TBL] [Abstract][Full Text] [Related]
19. Striking Size Reduction of Rapidly Growing Pancreatic Neuroendocrine Carcinoma Metastatic Nodal Conglomerate After Only 2 Cycles of 177 Lu-DOTATATE.
Somoza EA; Duan H; Shaheen S; Fischer GA; Aparici CM
Clin Nucl Med; 2022 Nov; 47(11):961-962. PubMed ID: 35695695
[TBL] [Abstract][Full Text] [Related]
20. Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (
Satapathy S; Bhattacharya A; Sood A; Kapoor R; Gupta R; Sood A; Sharma P; Khosla D; Mittal BR
Cancer Biother Radiopharm; 2022 Feb; 37(1):23-29. PubMed ID: 34185573
[No Abstract] [Full Text] [Related]
[Next] [New Search]
